Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 11, Issue 4 (Vol.11 No.4 Jan 2023)
rbmb.net 2023, 11(4): 702-709 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abdeen Radwan A, Abd-Elazeem Hefney N E, Mohammed Kholef E F, Elebidi A, Mahmoud H. Transforming Growth Factor Β as a Marker of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection. rbmb.net 2023; 11 (4) :702-709
URL: http://rbmb.net/article-1-965-en.html
URL: http://rbmb.net/article-1-965-en.html
Assem Abdeen Radwan * 
, Nour El-Dean Abd-Elazeem Hefney , Emad Farah Mohammed Kholef , Abdallah Elebidi , Hala Mahmoud
, Nour El-Dean Abd-Elazeem Hefney , Emad Farah Mohammed Kholef , Abdallah Elebidi , Hala Mahmoud
Department of Internal Medicine, Faculty of Medicine, Aswan University, Egypt.
Abstract: (1672 Views)
Background: The Transforming Growth Factor-beta (TGF-β) is one of the main growth factors associated with fibrosis or cirrhosis progression in the liver, but its role in hepatocarcinogenesis is controversial. To highlight the role of Transforming Growth Factor β as a marker of Hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection.
Methods: Ninety subjects were enrolled in this study, classified into three groups: Group I (chronic HCV group) included 30 patients with chronic HCV infection; Group II (HCC group) include 30 patients having HCC and chronic HCV infection and Group III consisted of 30 age and sex-matched healthy controls. TGF-β was evaluated in all the enrollees and its levels were correlated to liver function and other clinical parameters.
Results: TGF-β was found significantly higher in HCC group than in control and chronic HCV (P <0.001). In addition, it was correlated with biochemical and clinical parameters of cancer.
Conclusions: Patients with HCC showed increased level of TGF-β compared to chronic HCV infection patients and controls.
Methods: Ninety subjects were enrolled in this study, classified into three groups: Group I (chronic HCV group) included 30 patients with chronic HCV infection; Group II (HCC group) include 30 patients having HCC and chronic HCV infection and Group III consisted of 30 age and sex-matched healthy controls. TGF-β was evaluated in all the enrollees and its levels were correlated to liver function and other clinical parameters.
Results: TGF-β was found significantly higher in HCC group than in control and chronic HCV (P <0.001). In addition, it was correlated with biochemical and clinical parameters of cancer.
Conclusions: Patients with HCC showed increased level of TGF-β compared to chronic HCV infection patients and controls.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2022/06/7 | Accepted: 2022/06/23 | Published: 2023/04/3
Received: 2022/06/7 | Accepted: 2022/06/23 | Published: 2023/04/3
References
1. El-Serag HB. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-27. [DOI:10.1056/NEJMra1001683] [PMID]
2. Shaker O, Mahfouz H, Salama A, Medhat E. Long Non-Coding HULC and miRNA-372 as Diagnostic Biomarkers in Hepatocellular Carcinoma. Rep Biochem Mol Biol. 2020;9(2):230-240. [DOI:10.29252/rbmb.9.2.230] [PMID] [PMCID]
3. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61(1 Suppl):S14-25. [DOI:10.1016/j.jhep.2014.06.035] [PMID]
4. Lashgarian H E, Valibeik A, Marzban A, Karkhane M, Shahzamani K. The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B. Rep Biochem Mol Biol. 2021;10(2):233-242. [DOI:10.52547/rbmb.10.2.233] [PMID] [PMCID]
5. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1):58-68. [DOI:10.1016/j.jhep.2014.07.012] [PMID]
6. Yang JD, Roberts LR. Hepatic cancer: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448-58. [DOI:10.1038/nrgastro.2010.100] [PMID] [PMCID]
7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1. [DOI:10.1053/j.gastro.2011.12.061] [PMID] [PMCID]
9. Bellam N, Pasche B. TGF-β signaling alterations and colon cancer. Cancer Treat Res. 2010;155:85-103. [DOI:10.1007/978-1-4419-6033-7_5] [PMID]
10. Zhang L, Zhou F, Dijke P. Signaling interplay between transforming growth factor- β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci. 2013; 38:612-620. [DOI:10.1016/j.tibs.2013.10.001] [PMID]
11. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016; 22: 853-861. [DOI:10.1016/j.cmi.2016.07.019] [PMID]
12. Muñoz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, MuroCacho CA, Bàez A. Aberrant methylation inactivates transforming growth factor beta receptor 1 in head and neck squamous cell carcinoma. Int J Otolrayngol. 2009;209:12-20. [DOI:10.1155/2009/848695] [PMID] [PMCID]
13. Lee D, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, et al. Transforming growth factor beta 1 over expression is closely related to invasiveness of hepatocellular carcinoma. Oncology. 2012;82(1):11-8. [DOI:10.1159/000335605] [PMID]
14. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver. 1994;14(2):98-102. [DOI:10.1111/j.1600-0676.1994.tb00055.x] [PMID]
15. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3):421-430. [DOI:10.1016/S0168-8278(01)00130-1] [PMID]
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-9. [DOI:10.1002/bjs.1800600817] [PMID]
17. Abdel Salam, F., Omar, M., Mohammed, S., El- Bahy, A. Evaluation of Transforming Growth Factor- β 1 Gene Expression and Polymorphism in Diagnosis of Hepatocellular Carcinoma in HCV-Infected Patients. Benha Medical Journal, 2020; 37(Special issue (Internal medicine and Hepatology)): 47-67. [DOI:10.21608/bmfj.2020.111577]
18. Peng Q, Chunfang G, Meng F, Qiang J, Yunpeng Z, Yan L, Xiaojuan S. Establishment of a real-time PCR for quantifying transforming growth factor beta1 in blood of hepatocellular carcinoma patients. Journal of Medical Colleges of PLA. 2008;23(4): 228-236. [DOI:10.1016/S1000-1948(08)60047-7]
19. Baghdady I, Fouad F, Sayed M, Shoaib A, Salah Y, Elshayeb E, et al. Serum markers for the early detection of hepatocellular carcinoma in patients with chronic viral hepatitis C infection. Menoufia Med J. 2014;(27):544-550 [DOI:10.4103/1110-2098.145509]
20. El-Tayeh SF, Hussein TD, El-Houseini ME, Amer MA, El-Sherbini M, Elshemey WM. Serological biomarkers of hepatocellular carcinoma in Egyptian patients. Dis Markers. 2012;32(4):255-63. [DOI:10.1155/2012/962320] [PMID] [PMCID]
21. Yasmin Anum MY, Looi ML, Nor Aini AH, Merican I, Wahidah A, Mohd Radzi AH, et al. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. Med J Malaysia. 2009;64(3):223-7.
22. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O, et al. Transforming Growth Factor Beta1 and Soluble Fas Serum Levels in Hepatocellular Carcinoma. Cytokine. 2000;12 (6), 811-14. [DOI:10.1006/cyto.1999.0650] [PMID]
23. Kim HG, Chung YH, Song BC, Kim J, Yang SH, Lee YS, et al. Expression of transforming growth factor beta- 1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection. Korean J Intern Med. 2000;15(3):165-70. [DOI:10.3904/kjim.2000.15.3.165] [PMID] [PMCID]
24. Shirai M, Okada H, Nishioka M, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol. 1994;68(5):3334-42. [DOI:10.1128/jvi.68.5.3334-3342.1994] [PMID] [PMCID]
25. Farid IM, Hamza IM, El-Abd DM, Mohyi AM, AbdulLatif MM, Aref AT, Hamza DM. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report. Arab J Gastroenterol. 2014;15(3-4):142-7. [DOI:10.1016/j.ajg.2014.10.007] [PMID]
26. Elgendy SM, Hessien M, Elsherbiny MM, Abd El-Salam IM, El-Attar IA, El-Asser Ael-B. A panel of molecular markers in hepatitis C virus-related hepatocellular carcinoma. J Egypt Natl Canc Inst. 2005;17(4):270-8.
27. Hussein MM, Ibrahim NF, Khattab NF, El Fouly RF, El Fouly NF. Serum transforming growth factor beta1 in hepatitis c virus related chronic liver disease and hepatocellular carcinoma patients. Med J Cairo Univ. 2010; (78):279-286.
28. Elgamal S, Ghafar AA, Ghoneem E, Elshaer M, Alrefai H, Elmeshaty W. Characterization of patients with hepatocellular carcinoma on the way for early detection: one center experience. Egypt J Intern Med. 2018; (30): 231-238. [DOI:10.4103/ejim.ejim_29_18]
29. Morsy KH, Saif-Al-Islam M, Ibrahim EM. Hepatocellular Carcinoma in Upper Egypt: A Retrospective Study. ARC Journal of Hepatology and Gastroenterology. 2018; 3(1):8-17.
30. Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. Clin Infect Dis. 2016;63(6):723-9. [DOI:10.1093/cid/ciw362] [PMID]
31. Saini V, Madan K, Mittal VV, Sakhuja P, Sarin SK. Alpha-fetoprotein production by non-hepatocellular carcinoma, malignant liver tumor. Indian J Cancer. 2009;46(3):253-4. [DOI:10.4103/0019-509X.52970] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
